Asia-Pacific Dermatology Drugs Market is Expected to Grow at 10.5% in the Forecast Period of 2020 to 2027

Asia-Pacific Dermatology Drugs Market is growing with factors such as increasing prevalence of skin diseases and rising spending on health care and increase in risk of infections (VAP) and high cost of dermatology drugs may obstruct the growth of the market in the given forecast period.

Asia-Pacific Dermatology Drugs Market Scenario                                       

According to Data Bridge Market Research, the market for dermatology drugs in Asia-Pacific has the highest market share. Market leader is Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.) which accounts an estimated market share of approximately 15% to 20%. The company has gained outstanding sale through providing medical food.

  • In April 2020, Janssen Pharmaceuticals, Inc., a subsidiary of Johnson & Johnson Services, Inc. announced that it has submitted Biologics License Applications (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI ARIA. This is a novel treatment for the treatment of Psoriatic arthritis. If approved, it will lead to huge revenue generations.

Asia-Pacific Dermatology Drugs MarketTrends Impacting the Market

Now the question is which other regions Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.) and Galderma LABORATORIES, L.P. are targeting? Data Bridge Market Research has estimated a large growth in Asia-Pacific dermatology drugs market and the market leaders targeting Japan, China and India to be their next revenue pockets for 2020.

Dermatology drugs market is becoming more competitive with companies such as Abbvie Inc. and Mylan N.V. as they are the top dominating companies in dermatology drugs having maximum number of products. Data Bridge Market Research new reports highlight the major growth factors and opportunities in the Asia-Pacific dermatology drugs market.     

For more analysis on the Asia-Pacific dermatology drugs market request for a briefing with our analysts

Asia-Pacific Dermatology Drugs Market Development

  • In October 2019, AbbVie Inc., launched a platform by the name of “Let me be clear” which empowers the people to speak about and gain freedom from psoriasis. This will establish the credibility of the company.

Scope of the Asia-Pacific Dermatology Drugs Market 

Dermatology drugs market is segmented on the basis of countries into Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, and Rest of Asia-Pacific.

  • All country based analysis of Asia-Pacific dermatology drugs market is further analyzed based on further segmentation.
  • Asia-Pacific dermatology drugs market on the basis of drug class, the market is segmented into corticosteroids, retinoids, monoclonal antibodies, antibiotics agents, antiviral agents, antifungal drugs, antihistamines agents, immunosuppressive drugs and others. On the basis of drug type, the market is segmented into branded and generics. On the basis of indication, the market is segmented into infectious skin disease, inflammatory/autoimmune disorders, pigmentation disorders, skin cancer and others. On the basis of prescription mode, the market is segmented into prescription based drugs and over-the-counter drugs. On the basis of route of administration, the market is segmented into oral, topical and parenteral. On the basis of end user, the market is segmented into homecare, hospitals, dermatology clinics and others. On the basis of distribution channel, the market is segmented into retail pharmacy, hospitals pharmacy, online pharmacy and others.

To know more about the study

Key Pointers Covered in Asia-Pacific Dermatology Drugs Market Industry Trends and Forecast to 2027

  • Market Size
  • Top to Bottom Market Analysis
  • Recent Developments for Market Competitors
  • Recent Market Value for Different Countries

Key Market Competitors Covered in the Report

  • Novartis AG
  • Pfizer Inc.
  • Eli Lilly and Company.
  • Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.)
  • Almirall, S.A
  • Mylan N.V.
  • Sun Pharmaceutical Industries Ltd.
  • UCB S.A., Belgium
  • Glenmark Pharmaceuticals Limited
  • GlaxoSmithKline plc.
  • Galderma Laboratories, L.P
  • Teva Pharmaceutical Industries Ltd.
  • LEO Pharma A/S
  • Mayne Pharma Group Limited
  • AbbVie Inc.
  • Cipla Inc
  • Vibcare Pharma Pvt. Ltd
  • Ciaga

Above are the key players covered in the report, to know about more and exhaustive list of dermatology drugs companies’, contact us

Research Methodology: Asia-Pacific Dermatology Drugs Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include vendor positioning grid, market time line analysis, market overview and guide, company positioning grid, company market share analysis, standards of measurement, top to bottom analysis and vendor share analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

  • Demand Side: Clinicians and Technicians, Academic Professionals and Researchers
  • Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others

Related Reports

Browse in Healthcare Category Related Reports@